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Abstract
Background: The clinical effectiveness of complementary and alternative medicines (CAMs) is
widely debated because of a lack of clinical trials. The internet may provide an effective and
economical approach for undertaking randomised controlled trials (RCTs) of low-risk
interventions. We investigated whether the internet could be used to perform an internet-based
RCT of a CAM fulfilling the revised CONSORT (Consolidated Standards of Reporting Trials)
statement quality checklist for reporting of RCTs. A secondary aim was to examine the effect of
probiotics compared to placebo in terms of well-being over 12 weeks.
Methods:  People aged ≥18 years with confirmed spondyloarthropathy living in the United
Kingdom with internet access were invited to participate in an internet-based RCT of probiotic
compared to placebo for improving well-being and bowel symptoms. The intervention was a
probiotic containing 4 strains of live bacteria or identical placebo taken by mouth daily for 3
months. The primary outcome measure was the performance of the trial according to the revised
CONSORT statement.
Results: 147 people were randomised into the trial. The internet-based trial of the CAM fulfilled
the revised CONSORT statement such as efficient blinding, allocation concealment, intention to
treat analysis and flow of participants through the trial. Recruitment of the required number of
participants was completed in 19 months. Sixty-five percent (96/147) completed the entire 3
months of the trial. The trial was low cost and demonstrated that in an intention to treat analysis,
probiotics did not improve well-being or bowel symptoms.
Conclusion: The internet-based RCT proved to be a successful and economical method for
examining this CAM intervention. Recruitment, adherence and completion rate were all similar to
those reported with conventional RCTs but at a fraction of the cost. Internet-based RCTs can fulfil
all the criteria of the revised CONSORT statement and are an appropriate method for studying
low-risk interventions.
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Background
The use of complementary and alternative medicines
(CAMs) has increased considerably in the Western indus-
trialised countries in the past decade. CAMs are often used
for maintaining wellness and in addition conventional
care for chronic and acute health conditions [1]. However,
there is real debate around their use [2-4] because of the
lack of high quality scientific evidence for their effective-
ness. Randomised controlled trials (RCTs) are considered
the highest form of scientific evidence for any primary
research study. However, few RCTs have been performed
on CAMs as there is little incentive for manufacturers to
undertake the considerable financial investments
required for phase 1–4 clinical trials that assess efficacy,
effectiveness, safety and cost-effectiveness [5] when indi-
vidual CAMs may be provided by several providers and
can not be protected by patent. Also, many CAMs can be
marketed without the legal restrictions placed on drugs.
These barriers mean that the potential benefits of CAMs
are generally not adequately assessed, and patients may be
denied potentially effective and safe interventions from
the national health service.
Internet-based trials may provide a highly economical
way of overcoming many of these logistical and funding
barriers. Internet-based trials can cut down on cost of staff
time (including clinical costs and data entry time), allow
frequent contact with participants, enable recruitment
across a large area (national or international) instead of
requiring multi-centred study design and less common
conditions can be examined. We examined whether an
internet-based RCT could generate high quality evidence
regarding the effectiveness of a widely used CAM/food
supplement in a specific patient population by evaluating
the performance of the trial according to the revised CON-
SORT statement [6]
Our chosen intervention was probiotics in spondyloar-
thropathy (SpA a group of related disorders) as probiotics
have an excellent safety profile [7] and are considered a
food supplement. There is considerable evidence from
clinical and epidemiological studies that inflammation of
the gut is involved in triggering spondyloarthropathy [8-
11] and in the severity of the resultant joint inflammation
[12,13] Probiotics may help in treating this bowel inflam-
mation [14-16] and are advertised for ankylosing spond-
ylitis, the prototypic SpA on several commercial internet
sites, despite the absence of any published clinical trials.
Objectives
Primary
To examine if an internet-based RCT of a CAM can meet
the revised CONSORT statement quality checklist for
reporting of RCTs.
Secondary
To examine the effect of probiotic on well-being com-
pared to placebo.
Methods
Participants
Participants were recruited from a link posted on the web-
site of the national patient-led charity, the National Anky-
losing Spondylitis Society (NASS). The trial web site
provided information regarding the trial and stipulated
that participants had to be 18 years or over, resident in the
UK, have access to the internet and a diagnosis of SpA.
Participants printed-out and signed a consent form and
posted it to researchers. This included permission from
the participant for the research team to contact their doc-
tor (either general practitioner or rheumatologist) to con-
firm that they knew the participant, that the participant
was more than 18 years old, had a diagnosis of SpA made
by a rheumatologist and confirmed by X-ray or magnetic
resonance scan, and did not have a immunosuppressive
disorder such as HIV/AIDS or cancer. All the participants
included in the study had a confirmation from their rheu-
matologist or GP that they had sacroiliitis as diagnosed
using an X ray or MRI. Therefore, no participants have
peripheral arthropathy only.
We also asked for the doctor to confirm other conditions
such as iritis, psoriasis or inflammatory bowel disease.
Participants were asked to stop taking live yogurts or other
probiotic preparations for the duration of the study. Par-
ticipants were encouraged to phone the research team if
they required further information.
Interventions
The probiotic (10 g lyophilized powder containing live
bacteria: Lactobacillus salivarius (CUL61) 6.25 × 109 cfu
(colony forming units), Lactobacilllus paracasei (CUL08)
1.25 × 109cfu, Bifidobacterium infantis (CUL34) 1.25 × 109
cfuand Bifidobacterium bifidum (CUL20) 1.25 × 109 cfu)
and the placebo (10 g maltodextrin) capsule were the
same colour, size, smell and contained powder of identi-
cal appearance. Capsules were sent through the post and
participants were instructed to keep the capsules in the
refrigerator and take 1 capsule by mouth daily for 3
months.
Outcome measures
Outcome 1: to fulfil the revised CONSORT statement for
reporting of parallel-group randomised trials for an inter-
net-based RCT of a CAM (probiotics).
Outcome 2: Comparison of probiotic and placebo group
in terms of well-being, bowel symptoms and arthritis
severity (disease activity and function) after 12 weeks of
treatment.BMC Musculoskeletal Disorders 2008, 9:4 http://www.biomedcentral.com/1471-2474/9/4
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Sample size
We required a sample size of 140 participants for 95%
power at 5% significance level (two sided) to detect a clin-
ically relevant difference [17] in wellbeing of 1.5 (stand-
ard deviation 2.6) allowing for a 30% drop out rate. The
analysis was by intention to treat, with participants being
analysed according to the group to which they were ran-
domised. No interim analyses were planned or per-
formed.
Random allocation
Sequence generation
A random allocation sequence, without the use of blocks,
was generated by the manufacturer of the probiotic inter-
vention (Cultech Ltd., Port Talbot, UK) using a computer
generated random number sequence. The sequence allo-
cated participants on a 1:1 basis to either the probiotic or
placebo arms of the study.
Allocation concealment
The allocation sequence was held by the manufacturer
and was not accessible to the researchers until all data had
been collected, analysed, interpreted and findings given to
an independent researcher. The study team allocated par-
ticipants consecutively to the randomization number
sequence and, thereby, to the assigned trial intervention.
The individuals generating the random number sequence
were in a different site to those recruiting participants and
posting out the intervention, and no members of the
research team met any of the participants.
Blinding
Participants and researchers were blinded to group assign-
ment. No member of the research team had face-to-face
contact with any of the participants.
Statistical methods
The secondary end points were compared using general
linear models, taking into account baseline values, age,
sex and disease duration. Patients with complete and
missing data (i.e. missing questionnaires) were compared
to examine whether the assumption of data missing in a
non-random way could be rejected. At the end of the
study the manufacturers informed the research team
which participants were in Group A or Group B but the
identity of these groups was only revealed after analysis
had been completed and the results submitted to an inde-
pendent third-party. All patients who had completed at
least the baseline questionnaire were analysed in an inten-
tion to treat analysis.
Follow-up
Baseline data was collected using the secure trial internet
site and included sex, age at onset of disease symptoms,
flare of symptoms in the past 7 days and medication. On
the same day each week for 3 months, participants com-
pleted a 10 cm visual analog scale for the self assessment
of well-being [18], bowel symptoms (diarrhoea, stomach
pain, blood in stools), disease activity (pain, discomfort,
morning stiffness, fatigue and tenderness, all averaged to
give a composite score [19]) and function [20,21]. There
was also space to make additional comments regarding
their health or the trial intervention. Participants reported
on the number of study capsules that they had taken dur-
ing the previous week. Each week patients were contacted
by e-mail to remind them to complete the on-line ques-
tionnaire. If they did not complete a questionnaire they
were contacted by e-mail to find out why.
Ethical approval
Granted by London MREC ref 04/2/18 in 2004
Results
This internet-based RCT of a CAM (probiotic) was able to
fulfil the revised CONSORT statement quality checklist
for reporting of RCTs (Table 1)
Participants
Of 160 consent forms received, 147 (91.9%) were eligible
and were randomised (See Figure 1). Of 160 people giving
consent, only 1 person was excluded because of no reply
from their primary care practitioner or rheumatologist
(See Figure 1). There were 11 who we could not get the
diagnosis of SpA independently confirmed and one with-
drew consent. Participants were recruited from through-
out the UK including; Aberdeen, Brighton, Cornwall,
Huddersfield, London and Cardiff and all had the oppor-
tunity to phone the researcher to discuss the study prior to
consent. Participants showed good adherence to complet-
ing the weekly on-line questionnaire, with 65% (96/147)
completing the study for the entire 3 months. If we
remove the participants who were excluded (as a result of
moving out of the UK, or developing other medical con-
ditions) then adherence to completing the questionnaires
was 70%.
Recruitment
The website was made available to participants on 1st Sep-
tember 2004 and the site was closed 19 months later
(March 2006), when 147 participants had been ran-
domised.
Baseline data
The two groups were well balanced for baseline character-
istics (see Table 2). However, the probiotic group
appeared to have poorer function and global well-being,
and used more non-steroidal anti-inflammatory drugs
(NSAIDs).BMC Musculoskeletal Disorders 2008, 9:4 http://www.biomedcentral.com/1471-2474/9/4
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There was no significant difference in the baseline charac-
teristics of participants who did not complete the entire 3
months trial and those who were lost to follow-up (Those
completing the trial were 71.6% male (68/95), average
age 43.9, disease duration 20 years compared non-compl-
eters who were 64% male (25/39), age 41 and disease
duration 19 years). Therefore, the last recorded measure-
ment was carried forward for analysis for all participants.
There was no significant difference in the number of
patients stopping/starting doses of concurrent AS medica-
tion in the placebo compared to the intervention arm.
CAM Outcome
There was no statistically or clinically significant differ-
ence between placebo and probiotic groups in terms of
global well-being, bowel symptoms or severity of arthritis.
The estimated probiotic effect was a worsening in well-
being of 0.16 units on the 0–10 scale (with 0 being best
and 10 being worst), with the 95% confidence interval (-
0.6 to 0.93) well outside the bounds of clinical relevance
(a required change in well-being of approximately 1.5
units) (See Table 3 for details and other outcome meas-
ures).
Table 1: How an internet-based trial can meet the quality criteria of the revised CONSORT statement
PAPER SECTION Description
TITLE AND ABSTRACT How participants were allocated to interventions is comparable to traditional RCTs
INTRODUCTION Background Scientific background and explanation of rationale is comparable to traditional RCTs
METHODS Participants Eligibility criteria for participants needs to be confirmed by a third person as the researchers do not see 
the participants. In 159 out of 160 consent forms a reply was obtained from the participants' primary 
care physician or rheumatologist. Settings and locations are generally online and remote access in an 
internet-based trial.
Interventions Interventions in an internet-based trial can only be those that the participant administers themselves and 
are stable enough to be sent in the post. The probiotic intervention fulfilled both these requirements.
Objectives Specifying objectives and hypotheses is comparable to traditional RCTs
Outcomes Outcome measures for an internet-based RCT generally need to be self assessment measures. However, 
postage of samples (such as blood samples taken at the local hospital or primary care practice) could be 
feasible. The use of internet-based questionnaires to assess disease severity in SpA has previously been 
validated[21]
Sample size Determination of sample size, stopping rules and interim analysis are comparable to traditional RCTs
Randomization – sequence generation Randomization is comparable to traditional RCTs
Randomization – allocation concealment Allocation concealment is easier with an internet-based RCT as the researchers never meet the 
participants and can only randomise after the details of the participants have been entered into the data 
collection system. Researchers did not know who was in group A or B until after all data had been 
collected and the database cleaned. The identity of group A or B was not revealed until after all the 
analysis was completed. Participants never knew if they were in group A or B.
Randomisation – implementation The allocation sequence was generated by different individuals to those recruiting and to those giving the 
medication to participants. No member of the research team met the participants
Blinding (masking) Blinding is feasible using internet-based trials as participants are unlikely to meet in order to compare 
treatments, researchers never meet participants so have limited ability see effects of treatments and the 
analyst can be kept completely blinded as the database does not contain any reference to allocation 
groups until all data collection and data cleaning has been completed.
Statistical methods Statistical methods are comparable to traditional RCTs
RESULTS Participant flow Participant flows are comparable to traditional RCTs. However, participants can drop out without giving 
reasons. Therefore perhaps additional measures to follow people such as telephone contact, is needed.
Recruitment Dates defining the periods of recruitment and follow-up is comparable to traditional RCTs
Baseline data The characteristics collected are all self reported but can be validated by a third person such as the 
participants medical practitioner
Numbers analyzed Internet-based trial must use intention to treat as there is no way of assessing compliance. Internet-
based trials can measure pragmatic effectiveness and not efficacy
Outcomes and estimation Analysis presentation is comparable to traditional RCTs
Ancillary analysis Analysis for an internet-based RCT is comparable to that in traditional RCTs
Adverse events Adverse events are harder to report in an internet-based RCT than in a traditional RCT. There is 
reliance on the participants to report adverse events. This is the reason why internet-based trials can 
only be conducted on safe interventions.
DISCUSSION Interpretation Interpretation of an internet-based RCT is comparable to that of a traditional RCT
Generalizability Generalizability may be affected as participants are a very selected sample. Participants need to have 
access to the internet/e-mail, the knowledge to use the internet/e-mail and the motivation to self refer to 
join a trial. However, generalizability of traditional RCTs is compromised by the artificial environment of 
frequent clinical visits, this bias does not apply to the internet-based RCT.
Overall evidence Overall evidence in an internet-based RCT is comparable to that in a traditional trialBMC Musculoskeletal Disorders 2008, 9:4 http://www.biomedcentral.com/1471-2474/9/4
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Flow diagram of the progress through the probiotics trial Figure 1
Flow diagram of the progress through the probiotics trial.
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(n= 160) 
Not meeting inclusion 
criteria (n= 13) 
- Not SpA/awaiting confirmation 
by rheumatologist (n= 9) 
- Not registered with GP practice 
(n=2) 
- Withdrew consent (n=1) 
- No reply from GP (n=1)  
     Randomised  (n=147) 
Allocated to placebo (n=76) 
Received at least one dose of 
allocated intervention (n= 69) 
Withdrawn before starting study and did not 
receive allocated intervention (n=7). 
-  Moved out of UK (n=1) 
-  Medical problems  (n= 2) 
-  Probiotics not received and study 
closed  (n=2) 
-  No reason given (n=2) 
Allocated to probiotic (n=71) 
Received allocated at least one 
dose of intervention (n= 66) 
Withdrawn before starting study and did not 
receive allocated intervention (n=5) 
- Medical  problems  (n=2) 
-  Did not want to stop own probiotics 
(n= 1) 
-  No reason given (n=2) 
Lost to follow-up  (n=19),  
- Developed exclusion criteria (n=2)
 - New diagnosis queries AS (n=1) 
-  Moved out of UK (n=1) 
- Developed other medical problems 
(n=3) 
Discontinued intervention, 
-  Forgot to take tablets and felt 
follow-up not worthwhile 
(n=2) 
-  No benefit (n=2)
-  No reason given (n=10)
Lost to follow-up (n=20), 
     - Personal reasons/ bereavement 
(n=2)  
    - moved out of UK (n=1) 
- developed other medical problems 
(n=1) 
Discontinued intervention, 
-  Forgot to take tablets and felt 
follow-up was not worthwhile 
(n=1) 
-  No benefit (n=1)
-  Adverse events (n=2)
-  No reason given (n=12)
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-  Completed at least 60 days 
(n=50) 
-  Completed study (n=46) 
Excluded from follow-up (n=6) BMC Musculoskeletal Disorders 2008, 9:4 http://www.biomedcentral.com/1471-2474/9/4
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Adherence to medication
Of those who started the study (69 placebo and 66 probi-
otic), 3938 out of a possible 5796 (67.9% placebo) and
3748 out of a possible 5544 (67.6% probiotic) tablets
were reported to have been taken.
Adverse events
11 people reported adverse events that they felt could be
due to the trial interventions, 5 in the placebo group and
6 in the probiotic group. In the placebo group there were
reports of stomach cramps (3), indigestion (1) and gen-
eral decline in well being (1). In the probiotic group there
were reports of stomach cramps (3), indigestion (1), pain-
ful spots (1) and dizzy spells (1). In two cases the partici-
pants stopped the trial medication and reported by e-mail
that the symptoms had continued.
Discussion
This internet-based trial of a CAM worked well as assessed
by the revised CONSORT statement (Table 1) [6]. The
required number of participants were recruited from a
wide geographical area in a reasonable time frame and
92% of respondents were eligible for the trial. General
practitioners and rheumatologists confirmed participant's
identity and assessed eligibility for the trial without pay-
ment, suggesting a high level of support for this approach
to clinical research among clinicians.
Participants' compliance with the trial procedure was sat-
isfactory with 65% submitting all the required on-line
questionnaires and a reported 68% compliance with the
trial intervention. Future internet-based RCTs could
include more objective assessments than self reporting.
For example, participants could submit biological sam-
ples by post for detection of the intervention.
Participation in internet-based trials requires internet
access and self motivation to access the research website,
participants need to read the study information and then
submit a consent form. This might limit generlisabiltiy as
Table 2: Baseline characteristics of participants1
Placebo (n = 69) Probiotic (n = 65)
Age (s.d) 42.7 (12.7) 44.8 (12.1)
Disease duration (s.d) 20.3 (13.4) 20.3 (13.2)
Male (%) 45 (65.2) 49 (75.4)
Iritis2 (%) 13/58 (22.4) 14/52 (26.9)
Inflammatory bowel disease2 (%) 6/58 (10.4) 2/52 (3.9)
Medication
■  non-steroidal anti-inflammatory drug (%) 44/66 (66.7) 53/62 (85.5)
■  steroid (%) 2/67 (3.0) 0/63 (0.0)
■  disease modifying antirheumatic drug (%) 8/67 (11.9) 5/63 (7.9)
Global Well-being (scale 0–10) 3.2 (2.0) 4.1 (2.5)
Disease activity (scale 0–10) 3.5 (1.9) 4.1 (2.2)
Function (scale 0–10) 3.1 (2.5) 4.2 (3.0)
Notes
1. Values are mean (standard deviation) for continuous variables and number (percentage) for categorical variables
2. Confirmed by the participant's general practitioner or rheumatologist.
Table 3: Outcome variables
Placebo Probiotic Estimated Probiotic Effect*
Baseline Final % change Baseline Final % change Change in scale (95% CI). A positive 
value indicates a worsening in condition.
Intention to treat (n = 69 
& n = 65)
Global wellbeing (0–10 scale) 3.2 (2.0) 2.9 (2.3) 9.4% 4.1 (2.5) 3.7 (3.0) 9.8% 0.16 (-0.61 to 0.93)
Bowel symptoms
Diarrhoea (0 – 10 scale) 1.9 (2.7) 1.0 (1.7) 47% 1.8 (2.6) 1.4 (2.3) 22% 0.24 (-0.36 to 0.83)
Stomach pain (0–10 scale) 2.1 (2.6) 1.2 (1.6) 42% 2.0 (2.7) 1.4 (2.2) 30% 0.17 (-0.42 to 0.76)
Blood in stools (0–10 scale) 0.6 (1.8) 0.5 (1.6) 17% 0.6 (1.6) 0.4 (1.1) 33% -0.14 (-0.55 to 0.27)
Arthritis severity
Disease activity (0–10 scale) 3.5 (1.9) 2.9 (2.2) 17% 4.1 (2.2) 3.6 (2.6) 12% 0.20 (-0.47 to 0.86)
Function (0–10 scale) 3.1 (2.4) 2.8 (2.6) 9.7% 4.2 (2.9) 4.0 (3.2) 5% -0.04 (-0.50 to 0.43)
* General linear model, with probiotic effect adjusted for age, sex, disease duration and baseline levelsBMC Musculoskeletal Disorders 2008, 9:4 http://www.biomedcentral.com/1471-2474/9/4
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they may not be representative of the wider community.
However, the fact that the participants have themselves
initiated their involvement in the study demonstrates
motivation and may also encourage their compliance and
thus, increase validity of the findings.
Other factors are likely to discourage compliance in inter-
net-based clinical trials. Participants in traditional RCTs
may perceive a benefit from face-to-face contact with
health professionals and other members of the research
team. Although this may encourage compliance, it is
labour intensive and creates a somewhat artificial envi-
ronment for testing an intervention and the internet
approach may better stimulate the "real world" regarding
compliance with interventions. Thus, traditional RCTs
may be more suitable for explanatory RCTs and the inter-
net-based approach may be suitable for pragmatic RCTs.
Methods to increase compliance in internet studies might
include telephone contact with researchers, a requirement
to post back unused capsules, and alarms or reminders
that the intervention is due. Compliance in the probiotic
group may have been considerably higher if it had been
effective in reducing symptoms and improving well being.
Thus, generalizability of traditional RCTs suffers from the
artificial trial environment which does not occur in inter-
net-based RCTs [22].
The lack of direct contact with participants compromises
follow-up for adverse events. All of the published internet-
based studies to date have tested low-risk interventions.
They have included a trial of kava and valerian for anxiety
and insomnia [23], topical ointment for herpes labialis
[24] and a glucosamine for knee pain in osteoarthritis
[25]. Probiotics have an excellent safety record [7]. There-
fore, we considered this preparation to be suitable for test-
ing using this approach.
This trial was funded by a grant for £4977 from NASS
which covered the cost of the data collection, researcher
time, postage of medication and letters to doctors and
analysis (probiotics were provide free of charge and writ-
ing up time was not included in funding). This compares
favourably with the costs of traditional RCTs.
In this study the probiotic preparation was not found to
improve well-being, disease activity or function compared
to placebo. However, it could be argued that the sample
tested had long term advanced disease and probiotics may
be may be beneficial in the early stages of SpA or for peo-
ple with milder disease. In addition, it is possible that a
larger dose or different mixture of strains of probiotic may
have had a beneficial outcome.
In conclusion, we consider that internet-based RCT's are
an effective and economical way to test low risk interven-
tions where close follow-up for adverse events is not
required. This approach may be particularly suited to
CAMs, where traditional RCT's are unlikely to be under-
taken, to deliver the evidence-base required by the regula-
tory authorities [3,4,26]
Conclusion
An internet-based approach allowed us to perform a high
quality RCT according to the revised CONSORT statement
at low cost. Internet-based trials may be a cost-effective
approach for assessing low-risk interventions. In this
study probiotics showed no statistical or clinical signifi-
cant improvement in SpA.
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